Correction to: Adverse Events with d-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Works matching IS 11732563 AND DT 2022 AND VI 42 AND IP 3
Results: 12
1
2
The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 237, doi. 10.1007/s40261-022-01127-9
- By:
- Publication type:
- Article
3
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
Correction to: Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non‑Asian Patients with Atrial Fibrillation: A Systematic Review and Meta‑Analysis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
5
The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 221, doi. 10.1007/s40261-022-01125-x
- By:
- Publication type:
- Article
6
Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 253, doi. 10.1007/s40261-022-01124-y
- By:
- Publication type:
- Article
7
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
8
The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 243, doi. 10.1007/s40261-022-01122-0
- By:
- Publication type:
- Article
9
Significant Correlations between p-Cresol Sulfate and Mycophenolic Acid Plasma Concentrations in Adult Kidney Transplant Recipients.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 207, doi. 10.1007/s40261-022-01121-1
- By:
- Publication type:
- Article
10
Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 193, doi. 10.1007/s40261-022-01119-9
- By:
- Publication type:
- Article
11
Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 199, doi. 10.1007/s40261-022-01118-w
- By:
- Publication type:
- Article
12
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 263, doi. 10.1007/s40261-021-01115-5
- By:
- Publication type:
- Article